Tag: obesity treatment
Eli Lilly’s Tirzepatide approved by NMPA in China, boosting market position
Tirzepatide’s debut as the first dual GIP and GLP-1 receptor agonist for obesity in China strengthens Eli Lilly’s presence
Anti-obesity drugs to dominate biopharma trends in 2024, reports GlobalData
Survey reveals obesity medications as key driver for industry growth in biopharmaceutical sector